Skip to main content
SpringerLink
Log in

Management of Acute Renal Failure in the Elderly Patient

A Clinician’s Guide

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Numerous anatomical and functional changes occurring in the aging kidney lead to reduced glomerular filtration rate, lower renal blood flow and impaired renal autoregulation. The elderly are especially vulnerable to the development of renal dysfunction and in this population acute renal failure (ARF) is a common problem. ARF is often iatrogenic and multifactorial; common iatrogenic combinations include pre-existing renal dysfunction and exposure to nephrotoxins such as radiocontrast agents or aminoglycosides, use of NSAIDs in patients with congestive cardiac failure and use of ACE inhibitors and diuretics in patients with underlying atherosclerotic renal artery stenosis.

The aetiology of ARF is classically grouped into three categories: prerenal, intrinsic and postrenal. Prerenal ARF is the second most common cause of ARF in the elderly, accounting for nearly one-third of all hospitalized cases. Common causes can be grouped into true volume depletion (e.g. decreased fluid intake), decreased effective blood volume (e.g. systemic vasodilation) and haemodynamic (e.g. renal artery stenosis, NSAID use). Acute tubular necrosis (ATN) is the most common cause of intrinsic ARF and is responsible for over 50% of ARF in hospitalized patients, and up to 76% of cases in patients in intensive care units. ATN usually occurs after an acute ischaemic or toxic event. The pathogenesis of ATN involves an interplay of processes that include endothelial injury, microvascular flow disruption, tubular hypoxia, dysfunction and apoptosis, tubular obstruction and trans-tubular back-leak. Vasculitis causing ARF should not be missed as this condition is potentially life threatening. The likelihood of a postrenal cause for ARF increases with age. Benign prostatic hypertrophy, prostatic carcinoma and pelvic malignancies are all important causes. Early identification of ARF secondary to obstruction with renal imaging is essential, and complete or partial renal recovery usually ensues following relief of the obstruction.

A comprehensive medical and drug history and physical examination are all invaluable. Particular attention should be paid to the fluid status of the patient (skin turgor, jugular venous pressure, lying and standing blood pressure, urine output). Urinalysis should be performed to detect evidence of proteinuria and haematuria, which will aid diagnosis. Fractional excretion of sodium and urine osmolality may be measured but the widespread use of diuretics in the elderly gives rise to unreliable results. Renal imaging, usually ultrasound scanning, is routinely performed for assessment of renal size and to exclude urinary obstruction. In some cases, renal biopsy is necessary to provide specific diagnostic information.

The general principles of managing ARF include treatment of life-threatening features such as shock, respiratory failure, hyperkalaemia, pulmonary oedema, metabolic acidosis and sepsis; stopping and avoiding administration of nephrotoxins; optimization of haemodynamic and fluid status; adjustment of drug dosage appropriate to glomerular filtration rate; early nutritional support; and early referral to nephrologists for diagnosis of ARF cause, timely initiation of dialysis and initiation of specific treatment. The treatment of prerenal and ATN ARF is largely supportive with little evidence of benefit from current pharmacological therapies.

Despite advances in critical care medicine and renal replacement therapy, the mortality of ARF has not changed significantly over the last 40 years, with current mortality rates being up to 75%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74(2): 243–8

    PubMed  CAS  Google Scholar 

  2. Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change? J Am Soc Nephrol 2003; 14(8): 2178–87

    PubMed  Google Scholar 

  3. Bellomo R, Ronco C, Kellum JA, et al., and the ADQI workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–12

    PubMed  Google Scholar 

  4. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11(2): R31

    PubMed  Google Scholar 

  5. Orimo H. Reviewing the definition of elderly. Nippon Ronen Igakkai Zasshi 2006; 43(1): 27–34

    PubMed  Google Scholar 

  6. Pascual J, Orofino L, Liano F, et al. Incidence and prognosis of acute renal failure in older patients. J Am Geriatr Soc 1990; 38(1): 25–30

    PubMed  CAS  Google Scholar 

  7. Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ 1993; 306(6876): 481–3

    PubMed  CAS  Google Scholar 

  8. McLachlan M, Wasserman P. Changes in sizes and distensibility of the aging kidney. Br J Radiol 1981; 54(642): 488–91

    PubMed  CAS  Google Scholar 

  9. Thomas SE, Anderson S, Gordon KL, et al. Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J Am Soc Nephrol 1998; 9(2): 231–42

    PubMed  CAS  Google Scholar 

  10. Abrass CK, Adcox MJ, Raugi GJ. Aging-associated changes in renal extracellular matrix. Am J Pathol 1995; 146(3): 742–52

    PubMed  CAS  Google Scholar 

  11. Hoy WE, Douglas-Denton RN, Hughson MD, et al. A stereo-logical study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney Int Suppl 2003; (83): S31–7

    Google Scholar 

  12. Hollenberg NK, Adams DF, Solomon HS. Senescence and renal vasculature in normal man. Circ Res 1974; 34: 309–16

    PubMed  CAS  Google Scholar 

  13. Barton M, Lattmann T, d’Uscio LV, et al. Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease. J Cardiovasc Pharmacol 2000; 36 (5 Suppl. 1): S153–6

    PubMed  CAS  Google Scholar 

  14. Thompson MM, Oyama TT, Kelly FJ, et al. Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol 2000; 279(5): R1787–94

    PubMed  CAS  Google Scholar 

  15. Castellani S, Ungar A, Cantini C, et al. Excessive vasoconstriction after stress by the aging kidney: inadequate prostaglandin modulation of increased endothelin activity. J Lab Clin Med 1998; 132(3): 186–94

    PubMed  CAS  Google Scholar 

  16. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1): 1–12

    PubMed  Google Scholar 

  17. Bleyer AJ, Shemanski LR, Burke GL, et al. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000; 57(5): 2072–9

    PubMed  CAS  Google Scholar 

  18. Sands JM. Urine-concentrating ability in the aging kidney. Sci Aging Knowledge Environ 2003; 2003(24): PE15

    PubMed  Google Scholar 

  19. Davidman M, Olson P, Kohen J, et al. Iatrogenic renal disease. Arch Intern Med 1991; 151(9): 1809–12

    PubMed  CAS  Google Scholar 

  20. Kohli HS, Bhaskaran MC, Muthukumar T, et al. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant 2000; 15(2): 212–7

    PubMed  CAS  Google Scholar 

  21. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 1996; 50(3): 811–8

    PubMed  CAS  Google Scholar 

  22. Pascual J, Liano F. Causes and prognosis of acute renal failure in the very old: Madrid Acute Renal Failure Study Group. J Am Geriatr Soc 1998; 46(6): 721–5

    PubMed  CAS  Google Scholar 

  23. Kenney WL, Chiu P. Influence of age on thirst and fluid intake. Med Sci Sports Exerc 2001; 33(9): 1524–32

    PubMed  CAS  Google Scholar 

  24. van Kraaij DJ, Jansen RW, Gribnau FW, et al. Diuretic therapy in elderly heart failure patients with and without left ventricular systolic dysfunction. Drugs Aging 2000; 16(4): 289–300

    PubMed  Google Scholar 

  25. Piraino AJ. Managing medication in the elderly. Hosp Pract (Minneap) 1995; 30(6): 59–64

    CAS  Google Scholar 

  26. Baraldi A, Ballestri M, Rapana R, et al. Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 1998; 13Suppl. 7: 25–9

    PubMed  Google Scholar 

  27. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32(1): 1–12

    PubMed  CAS  Google Scholar 

  28. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45(3): 531–9

    PubMed  CAS  Google Scholar 

  29. Motola D, Vaccheri A, Silvani MC, et al. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004; 60(10): 731–8

    PubMed  Google Scholar 

  30. Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 2003; 20(9): 701–10

    PubMed  CAS  Google Scholar 

  31. Johnson AG, Simons LA, Simons J, et al. Non-steroidal antiinflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol 1993; 35(5): 455–9

    PubMed  CAS  Google Scholar 

  32. Jones AC, Berman P, Doherty M. Non-steroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. Br J Rheumatol 1992; 31(1): 45–8

    PubMed  CAS  Google Scholar 

  33. Fraenkel L, Wittink DR, Concato J, et al. Informed choice and the widespread use of antiinflammatory drugs. Arthritis Rheum 2004; 51(2): 210–4

    PubMed  Google Scholar 

  34. Cheung CM, Shaheen N, Shurrab AE, et al. Use and effects of ACE inhibitors and angiotensin II receptor blockers in patients with atherosclerotic renovascular disease (ARVD) [abstract no. RA4583]. Renal Association Conference; 2004 Sep; London

  35. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50(7): 1297–300

    PubMed  Google Scholar 

  36. Kalra PA, Mamtora H, Holmes AM, et al. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med 1990; 77(282): 1013–8

    PubMed  CAS  Google Scholar 

  37. Bridoux F, Hazzan M, Pallot JL, et al. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7(2): 100–4

    PubMed  CAS  Google Scholar 

  38. Kalra PA, Kumwenda M, MacDowall P, et al. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ 1999; 318(7178): 234–7

    PubMed  CAS  Google Scholar 

  39. Liano F, Junco E, Pascual J, et al. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings: the Madrid Acute Renal Failure Study Group. Kidney Int Suppl 1998; 66: S16–24

    PubMed  CAS  Google Scholar 

  40. Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units: causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24(2): 192–8

    PubMed  CAS  Google Scholar 

  41. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351(2): 159–69

    PubMed  CAS  Google Scholar 

  42. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14(8): 2199–210

    PubMed  Google Scholar 

  43. Myers BD, Chui F, Hilberman M, et al. Transtubular leakage of glomerular filtrate in human acute renal failure. Am J Physiol 1979; 237(4): F319–25

    PubMed  CAS  Google Scholar 

  44. Solez K, Morel-Maroger L, Sraer JD. The morphology of “acute tubular necrosis” in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58(5): 362–76

    CAS  Google Scholar 

  45. Anderson RJ, Linas SL, Berns AS, et al. Nonoliguric acute renal failure. N Engl J Med 1977; 296(20): 1134–8

    PubMed  CAS  Google Scholar 

  46. Dixon BS, Anderson RJ. Nonoliguric acute renal failure. Am J Kidney Dis 1985; 6(2): 71–80

    PubMed  CAS  Google Scholar 

  47. Rahman SN, Conger JD. Glomerular and tubular factors in urine flow rates of acute renal failure patients. Am J Kidney Dis 1994; 23(6): 788–93

    PubMed  CAS  Google Scholar 

  48. Liangos O, Rao M, Balakrishnan VS, et al. Relationship of urine output to dialysis initiation and mortality in acute renal failure. Nephron Clin Pract 2005; 99(2): c56–60

    PubMed  Google Scholar 

  49. Cronan JJ. Contemporary concepts in imaging urinary tract obstruction. Radiol Clin North Am 1991; 29: 527–42

    PubMed  CAS  Google Scholar 

  50. Naidich JB, Rackson ME, Mossey RT, et al. Nondilated obstructive uropathy: percutaneous nephrostomy performed to reverse renal failure. Radiology 1986; 160(3): 653–7

    PubMed  CAS  Google Scholar 

  51. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41

    PubMed  CAS  Google Scholar 

  52. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 461–70

    PubMed  CAS  Google Scholar 

  53. Pedone C, Corsonello A, Incalzi RA. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006; 35(2): 121–6

    PubMed  Google Scholar 

  54. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40(2): 221–6

    PubMed  CAS  Google Scholar 

  55. Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309(25): 1543–6

    PubMed  CAS  Google Scholar 

  56. Schwab SJ, Christensen RL, Dougherty K, et al. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147(5): 943–4

    PubMed  CAS  Google Scholar 

  57. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 2002; 62(6): 2223–9

    PubMed  CAS  Google Scholar 

  58. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007; 18: 2636–43

    PubMed  CAS  Google Scholar 

  59. Haas M, Spargo BH, Wit EJ, et al. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35(3): 433–47

    PubMed  CAS  Google Scholar 

  60. Kingswood JC, Banks RA, Tribe CR, et al. Renal biopsy in the elderly: clinicopathological correlations in 143 patients. Clin Nephrol 1984; 22(4): 183–7

    PubMed  CAS  Google Scholar 

  61. Ferro G, Dattolo P, Nigrelli S, et al. Clinical pathological correlates of renal biopsy in elderly patients. Clin Nephrol 2006; 65(4): 243–7

    PubMed  CAS  Google Scholar 

  62. Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002; 137(9): 744–52

    PubMed  Google Scholar 

  63. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition: the Mini Nutritional Assessment. Clin Geriatr Med 2002; 18(4): 737–57

    PubMed  Google Scholar 

  64. Druml W. Nutritional management of acute renal failure. J Ren Nutr 2005; 15(1): 63–70

    PubMed  Google Scholar 

  65. Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria: NORASEPT II Study Investigators. Am J Med 1999; 107(4): 387–90

    PubMed  CAS  Google Scholar 

  66. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356(9248): 2139–43

    PubMed  CAS  Google Scholar 

  67. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142(7): 510–24

    PubMed  CAS  Google Scholar 

  68. Lauschke A, Teichgraber UK, Frei U, et al. ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69(9): 1669–74

    PubMed  CAS  Google Scholar 

  69. Power DA, Duggan J, Brady HR. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol Suppl 1999; 26: S23–8

    PubMed  CAS  Google Scholar 

  70. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, doubleblind, placebo-controlled, randomized study. Nephrol Dial Transplant 1997; 12(12): 2592–6

    PubMed  CAS  Google Scholar 

  71. Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44(3): 402–9

    PubMed  CAS  Google Scholar 

  72. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288(20): 2547–53

    PubMed  CAS  Google Scholar 

  73. Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15(2): 90–6

    PubMed  CAS  Google Scholar 

  74. Shaw SG, Weidmann P, Hodler J, et al. Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J Clin Invest 1987; 80(5): 1232–7

    PubMed  CAS  Google Scholar 

  75. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994; 45(6): 1731–8

    PubMed  CAS  Google Scholar 

  76. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32(6): 1310–5

    PubMed  Google Scholar 

  77. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis: Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336(12): 828–34

    PubMed  CAS  Google Scholar 

  78. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure: Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36(4): 767–74

    PubMed  CAS  Google Scholar 

  79. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27(9): 1832–7

    PubMed  CAS  Google Scholar 

  80. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2002; 19(1): 32–9

    PubMed  CAS  Google Scholar 

  81. Caimmi PP, Pagani L, Micalizzi E, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2003; 17(4): 491–4

    PubMed  Google Scholar 

  82. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290(17): 2284–91

    PubMed  CAS  Google Scholar 

  83. Kim YK, Yoo JH, Woo JS, et al. Effect of pentoxifylline on ischemic acute renal failure in rabbits. Ren Fail 2001; 23(6): 757–72

    PubMed  CAS  Google Scholar 

  84. Kim YK, Choi TR, Kwon CH, et al. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren Fail 2003; 25(6): 909–22

    PubMed  CAS  Google Scholar 

  85. Shifow AA, Naidu MU, Kumar KV, et al. Effect of pentoxifylline on cyclosporine-induced nephrotoxicity in rats. Indian J Exp Biol 2000; 38(4): 347–52

    PubMed  CAS  Google Scholar 

  86. Lin F, Cordes K, Li L, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemiareperfusion injury in mice. J Am Soc Nephrol 2003; 14(5): 1188–99

    PubMed  Google Scholar 

  87. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15(7): 1794–804

    PubMed  Google Scholar 

  88. Star RA. Treatment of ARF. Kidney Int 1998; 54: 1817–31

    PubMed  CAS  Google Scholar 

  89. Himmelfarb J, Tolkoff RN, Chandran P, et al. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9(2): 257–66

    PubMed  CAS  Google Scholar 

  90. Parker RA, Himmelfarb J, Tolkoff-Rubin N, et al. Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study. Am J Kidney Dis 1998; 32(3): 432–43

    PubMed  CAS  Google Scholar 

  91. Schiffl H, Lang SM, Konig A, et al. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344(8922): 570–2

    PubMed  CAS  Google Scholar 

  92. Vinsonneau C, Camus C, Combes A, et al. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 2006; 368(9533): 379–85

    PubMed  Google Scholar 

  93. Lameire N, Hoste E, Van LA, et al. Pathophysiology, causes, and prognosis of acute renal failure in the elderly. Ren Fail 1996; 18(3): 333–46

    PubMed  CAS  Google Scholar 

  94. Gentric A, Cledes J. Immediate and long-term prognosis in acute renal failure in the elderly. Nephrol Dial Transplant 1991; 6(2): 86–90

    PubMed  CAS  Google Scholar 

  95. Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients. Nephrol Dial Transplant 2006; 21(5): 1248–52

    PubMed  Google Scholar 

  96. Bhandari S, Turney JH. Survivors of acute renal failure who do not recover renal function. QJM 1996; 89(6): 415–21

    PubMed  CAS  Google Scholar 

  97. Spurney RF, Fulkerson WJ, Schwab SJ. Acute renal failure in critically ill patients: prognosis for recovery of kidney function after prolonged dialysis support. Crit Care Med 1991; 19(1): 8–11

    PubMed  CAS  Google Scholar 

  98. Mehta RL, McDonald B, Gabbai FB, et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001; 60(3): 1154–63

    PubMed  CAS  Google Scholar 

  99. Liano F, Felipe C, Tenorio MT, et al. Long-term outcome of acute tubular necrosis: a contribution to its natural history. Kidney Int 2007; 71(7): 679–86

    PubMed  CAS  Google Scholar 

  100. Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int 2006; 70(6): 1120–6

    PubMed  CAS  Google Scholar 

  101. Chertow GM, Lazarus JM, Paganini EP, et al. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis: the Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998; 9(4): 692–8

    PubMed  CAS  Google Scholar 

  102. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16(11): 3365–70

    PubMed  Google Scholar 

  103. Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9(6): R700–9

    PubMed  Google Scholar 

  104. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294(7): 813–8

    PubMed  CAS  Google Scholar 

  105. Fiaccadori E, Lombardi M, Leonardi S, et al. Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: a prospective cohort study. J Am Soc Nephrol 1999; 10(3): 581–93

    PubMed  CAS  Google Scholar 

  106. Brivet F, Delfraissy JF, Balavoine JF, et al. Acute kidney failure: age is not a factor in the prognosis. Nephrologie 1983; 4(1): 14–7

    PubMed  CAS  Google Scholar 

  107. Lameire N, Matthys E, Vanholder R, et al. Causes and prognosis of acute renal failure in elderly patients. Nephrol Dial Transplant 1987; 2(5): 316–22

    PubMed  CAS  Google Scholar 

  108. Mehta RL, McDonald B, Gabbai F, et al. Nephrology consultation in acute renal failure: does timing matter? Am J Med 2002; 113(6): 456–61

    PubMed  Google Scholar 

  109. Khan IH, Catto GR, Edward N, et al. Acute renal failure: factors influencing nephrology referral and outcome. Q J Med 1997; 90(12): 781–5

    CAS  Google Scholar 

  110. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990; 150(6): 1237–42

    PubMed  CAS  Google Scholar 

  111. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med 1989; 110(2): 119–24

    PubMed  CAS  Google Scholar 

  112. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast- associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol 1991; 157(1): 49–58

    PubMed  CAS  Google Scholar 

  113. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320(3): 143–9

    PubMed  CAS  Google Scholar 

  114. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47(1): 254–61

    PubMed  CAS  Google Scholar 

  115. Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86 (6 Pt 1): 649–52

    PubMed  CAS  Google Scholar 

  116. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343(3): 180–4

    PubMed  CAS  Google Scholar 

  117. Mueller C, Seidensticker P, Buettner HJ, et al. Incidence of contrast nephropathy in patients receiving comprehensive intravenous and oral hydration. Swiss Med Wkly 2005; 135(19–20): 286–90

    PubMed  Google Scholar 

  118. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291(19): 2328–34

    PubMed  CAS  Google Scholar 

  119. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40(8): 1383–8

    PubMed  CAS  Google Scholar 

  120. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289(5): 553–8

    PubMed  CAS  Google Scholar 

  121. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62(6): 2202–7

    PubMed  CAS  Google Scholar 

  122. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40(2): 298–303

    PubMed  CAS  Google Scholar 

  123. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89(3): 356–8

    PubMed  CAS  Google Scholar 

  124. Shah SJ, Hsu CY. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study. Am J Med 2004; 117(12): 948–52

    PubMed  Google Scholar 

  125. Coyle LC, Rodriguez A, Jeschke RE, et al. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J 2006; 151(5): 1032–12

    PubMed  CAS  Google Scholar 

  126. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004; 148(3): 422–9

    PubMed  CAS  Google Scholar 

  127. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41(12): 2114–8

    PubMed  Google Scholar 

  128. Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15(2): 407–10

    PubMed  CAS  Google Scholar 

  129. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362(9384): 598–603

    PubMed  CAS  Google Scholar 

  130. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43(1): 1–9

    PubMed  CAS  Google Scholar 

  131. Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65(4): 1366–74

    PubMed  CAS  Google Scholar 

  132. Liu R, Nair D, Ix J, et al. N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and metaanalysis. J Gen Intern Med 2005; 20(2): 193–200

    PubMed  Google Scholar 

  133. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A metaanalysis. Am J Med 2004; 117(12): 938–47

    PubMed  CAS  Google Scholar 

  134. Zagler A, Azadpour M, Mercado C, et al. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 2006; 151(1): 140–5

    PubMed  CAS  Google Scholar 

  135. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996; 275(19): 1489–94

    PubMed  CAS  Google Scholar 

  136. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118(8): 843–9

    PubMed  CAS  Google Scholar 

  137. Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60(3): 176–82

    PubMed  CAS  Google Scholar 

  138. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111(9): 692–8

    PubMed  CAS  Google Scholar 

  139. Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43(2): 414–9

    PubMed  CAS  Google Scholar 

  140. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117(1): 39–50

    PubMed  CAS  Google Scholar 

  141. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53(3): 796–8

    PubMed  CAS  Google Scholar 

  142. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitic: EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53(3): 743–53

    PubMed  CAS  Google Scholar 

  143. Shin JH, Pyo HJ, Kwon YJ, et al. Renal biopsy in elderly patients: clinicopathological correlation in 117 Korean patients. Clin Nephrol 2001; 56(1): 19–26

    PubMed  CAS  Google Scholar 

  144. Labeeuw M, Colon S, Caillette A, et al. Renal histological findings in elderly adults over 75 years of age. Contrib Nephrol 1993; 105: 147–51

    PubMed  CAS  Google Scholar 

  145. Nachman PH, Hogan SL, Jennette JC, et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7(1): 33–9

    PubMed  CAS  Google Scholar 

  146. Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis: the Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20(3): 261–9

    PubMed  CAS  Google Scholar 

  147. Mekhail TM, Hoffman GS. Long-term outcome of Wegener’s granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 2000; 27(5): 1237–40

    PubMed  CAS  Google Scholar 

  148. Aasarod K, Iversen BM, Hammerstrom J, et al. Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15(5): 611–8

    PubMed  CAS  Google Scholar 

  149. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6): 488–98

    PubMed  CAS  Google Scholar 

  150. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52(8): 2461–9

    PubMed  Google Scholar 

  151. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349(1): 36–44

    PubMed  CAS  Google Scholar 

  152. Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40(4): 757–63

    PubMed  CAS  Google Scholar 

  153. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17(8): 2264–74

    PubMed  Google Scholar 

  154. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18(7): 2180–8

    PubMed  CAS  Google Scholar 

  155. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA- associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41(4): 776–84

    PubMed  Google Scholar 

  156. Slot MC, Tervaert JW, Franssen CF, et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63(2): 670–7

    PubMed  Google Scholar 

  157. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43(5): 1021–32

    PubMed  CAS  Google Scholar 

  158. Jayne D. Current attitudes to the therapy of vasculitis. Kidney Blood Press Res 2003; 26(4): 231–9

    PubMed  Google Scholar 

  159. Schwartz CJ, White TA. Stenosis of the renal artery: an un-selected necropsy study. BMJ 1964; 2: 1415–21

    PubMed  CAS  Google Scholar 

  160. Cheung CM, Hegarty J, Kalra PA. Dilemmas in the management of renal artery stenosis. Br Med Bull 2005; 73–74: 35–55

    PubMed  Google Scholar 

  161. Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003; 14(6): 1584–90

    PubMed  Google Scholar 

  162. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol 2003; 42(2): 211–6

    PubMed  Google Scholar 

  163. Thadhani RI, Camargo Jr CA, Xavier RJ, et al. Atheroembolic renal failure after invasive procedures: natural history based on 52 histologically proven cases. Medicine (Baltimore) 1995; 74(6): 350–8

    CAS  Google Scholar 

  164. Gupta BK, Spinowitz BS, Charytan C, et al. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator. Am J Kidney Dis 1993; 21(6): 659–62

    PubMed  CAS  Google Scholar 

  165. Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82(6): 1233–7

    PubMed  CAS  Google Scholar 

  166. Rudnick MR, Berns JS, Cohen RM, et al. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism. A critical review. Am J Kidney Dis 1994; 24(4): 713–27

    PubMed  CAS  Google Scholar 

  167. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19(1): 8–11

    PubMed  Google Scholar 

  168. Pusey CD, Saltissi D, Bloodworth L, et al. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med 1983; 52(206): 194–211

    PubMed  CAS  Google Scholar 

  169. Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978; 65(5): 756–65

    PubMed  CAS  Google Scholar 

  170. Buysen JG, Houthoff HJ, Krediet RT, et al. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5(2): 94–9

    PubMed  CAS  Google Scholar 

  171. Bagshaw SM. Epidemiology of renal recovery after acute renal failure. Curr Opin Crit Care 2006; 12(6): 544–50

    PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston, PR2 9HT, UK

    Ching M. Cheung, Arvind Ponnusamy & John G. Anderton

Authors
  1. Ching M. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arvind Ponnusamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John G. Anderton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ching M. Cheung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheung, C.M., Ponnusamy, A. & Anderton, J.G. Management of Acute Renal Failure in the Elderly Patient. Drugs Aging 25, 455–476 (2008). https://doi.org/10.2165/00002512-200825060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200825060-00002

Keywords

Search

Navigation